|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunosuppressants |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismNav1.9 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
注射用聚乙二醇伊立替康联合替莫唑胺用于脑胶质瘤II期临床研究
[Translation] Phase II clinical study of polyethylene glycol irinotecan combined with temozolomide for brain glioma
主要目的
评价注射用聚乙二醇伊立替康联合替莫唑胺对脑胶质瘤受试者的安全性、耐受性
次要目的
1) 初步观察注射用聚乙二醇伊立替康联合替莫唑胺对脑胶质瘤受试者的有效性,为后续临床试验推荐剂量和给药方式提供依据
2) 考察注射用聚乙二醇伊立替康联合替莫唑胺联合用药在脑胶质瘤受试者体内的药代动力学特性,获取联合用药后的药代动力学参数
[Translation] main purpose
To evaluate the safety and tolerability of polyethylene glycol irinotecan for injection combined with temozolomide in glioma subjects
secondary purpose
1) Preliminary observation of the efficacy of polyethylene glycol irinotecan for injection combined with temozolomide on glioma subjects, to provide the basis for the recommended dose and administration method for subsequent clinical trials
2) Investigate the pharmacokinetic properties of the combination of polyethylene glycol irinotecan for injection and temozolomide in glioma subjects, and obtain the pharmacokinetic parameters after the combination
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With Small Cell Lung Cancer
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
JK1201I单次联合多次给药在小细胞肺癌患者中的安全性、耐受性及初步有效性研究
[Translation] Study on the safety, tolerability and preliminary efficacy of JK1201I in combination with multiple doses in patients with small cell lung cancer
主要目的:
1) 评价JK1201I对小细胞肺癌患者的安全性和耐受性;
2) 确定JK1201I的剂量限制性毒性(DLT)和最大耐受剂量(MTD)。
次要目的:
1) 考察JK1201I在小细胞肺癌患者体内的药代动力学特性;
2) 观察JK1201I的初步疗效 。
[Translation] main purpose:
1) To evaluate the safety and tolerability of JK1201I in patients with small cell lung cancer;
2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of JK1201I.
Secondary purpose:
1) To investigate the pharmacokinetic properties of JK1201I in patients with small cell lung cancer;
2) To observe the preliminary curative effect of JK1201I.
100 Clinical Results associated with Jenkem Technology Co., Ltd.
0 Patents (Medical) associated with Jenkem Technology Co., Ltd.
2016·Material Matters (St. Louis, MO, United States)
Applications of Y-shape PEG derivatives: for drug delivery
100 Deals associated with Jenkem Technology Co., Ltd.
100 Translational Medicine associated with Jenkem Technology Co., Ltd.